Context Therapeutics (CNTX) Current Assets (2020 - 2026)
Context Therapeutics (CNTX) posted Current Assets of $58.5 million for Q1 2026, down 14.39% sequentially from $68.4 million in Q4 2025, and down 36.9% YoY from $92.7 million in Q1 2025.
Context Therapeutics (CNTX) Current Assets (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Current Assets for 7 years, with the latest figure at $58.5 million in Q1 2026.
- Quarterly Current Assets fell 36.9% year-over-year to $58.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.5 million (down 36.9% YoY) and the FY2025 annual result came in at $68.4 million, down 30.18% from the prior year.
- Current Assets eased to $58.5 million in Q1 2026 per CNTX's latest filing, from $68.4 million in the prior quarter.
- Over five years, Current Assets peaked at $102.7 million in Q2 2024 and troughed at $11.0 million in Q1 2024.
- A 5-year average of $56.1 million and a median of $46.9 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2024: Current Assets soared 9485.42% in 2022, then tumbled 65.38% in 2024.
- Over 5 years, Current Assets stood at $37.9 million in 2022, then tumbled by 57.61% to $16.0 million in 2023, then surged by 510.05% to $97.9 million in 2024, then sank by 30.18% to $68.4 million in 2025, then decreased by 14.39% to $58.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $58.5 million, $68.4 million, and $79.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - | 45.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.82 Mn |
| Mar 31, 2026 | 58.52 Mn |
| Dec 31, 2025 | 68.35 Mn |
| Sep 30, 2025 | 79.06 Mn |
| Jun 30, 2025 | 86.95 Mn |
| Mar 31, 2025 | 92.73 Mn |
| Dec 31, 2024 | 97.90 Mn |
| Sep 30, 2024 | 86.07 Mn |
| Jun 30, 2024 | 102.70 Mn |
| Mar 31, 2024 | 11.04 Mn |
| Dec 31, 2023 | 16.05 Mn |
| Sep 30, 2023 | 22.97 Mn |
| Jun 30, 2023 | 27.71 Mn |
| Mar 31, 2023 | 31.89 Mn |
| Dec 31, 2022 | 37.85 Mn |
| Sep 30, 2022 | 41.94 Mn |
| Jun 30, 2022 | 44.50 Mn |
| Mar 31, 2022 | 46.86 Mn |
| Dec 31, 2021 | 51.26 Mn |
| Sep 30, 2021 | 437,531.00 |